Avita Medical, Inc.: financial statements

RCELNASDAQHealthcare · Surgical & Medical Instruments & Apparatus

Price

$15.22

November 16, 2026Market cap $466M

What Ploutos Investor adds for Avita Medical

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 9 fiscal years, from FY2017
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.

Financial statements

Each fiscal year's income statement, balance sheet and cash flow as the company filed them, and the latest quarters.

2023–2025 fiscal years

Click a line to see it on the chart.

Revenue

+19.5% a year over 2 years

Line202320242025Average a year
Revenue $50M$64M$72M+19.5%
Cost of revenue $7.8M$9.1M$13M+28.2%
Gross profit $42M$55M$59M+17.8%
Operating income -$43M-$57M-$43M
Net income -$35M-$62M-$49M
Earnings per share $1.40-$2.39-$1.74
Earnings per share, basic $1.40-$2.39-$1.74
Margins
Gross margin 84.5%85.8%82.1%
Operating margin -85.1%-88.1%-59.4%
Net margin -70.6%-96.3%-67.8%

Financial statements

RCEL's revenue, profits and cash flows from FY2017 to 2022, 6 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

By segment

Revenue and operating income by business segment or by product, as the company itself reports them in each year's 10-K. Each year from the latest filing that carries it, so a segment renamed or re-cut shows in its current form.

  • 2023: United States $46M, Japan $3.4M, United Kingdom $141.0K, Australia $222.0K, European Union $51.0K
  • 2024: United States $62M, Japan $1.4M, United Kingdom $196.0K, Australia $312.0K, European Union $155.0K
  • 2025: United States $69M, Japan $2.1M, United Kingdom $486.0K, Australia $200.0K, European Union $49.0K
Country or region202320242025Share 2025
United States$46M$62M$69M96%
Japan$3.4M$1.4M$2.1M2.9%
United Kingdom$141.0K$196.0K$486.0K0.7%
Australia$222.0K$312.0K$200.0K0.3%
European Union$51.0K$155.0K$49.0K0.1%

By segment

RCEL's revenue by region from 2022 to 2022, 1 more fiscal year

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 4 fiscal years.

From the XBRL of 7 of the company's annual reports to the SEC (ASC 280). Amounts in dollars.

Amounts are in dollars as the company filed them in its annual reports (10-K or 20-F). Those reporting in another currency are converted at each fiscal year-end rate. Shares and earnings per share are adjusted for splits.

Debt and obligations

What the company owes beyond the loans on its balance sheet, and when it pays, from the notes to its annual report: debt maturities, leases, pension plans, goodwill by segment, and how it gets to the tax it pays.

$3.1M Leases-0.0% Effective tax rate

The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.

Leases

Dec 31, 2025

Operating leases

$3.1M

Finance leases

–

The liability is the present value of the rent still to pay, at December 31, 2025. It is not counted in the ladder's debt. The filing

From the statutory to the effective tax rate, 2025

Dec 31, 2025

Statutory rate

21.0%

Effective rate

-0.0%

-21.0 pts

The company paid -0.0% in tax on its profit, 21.0 points below the US federal rate (21.0%). Below, the reasons it gives.

Statutory rate

21.0%

Change in valuation allowance

-20.0 pts

Difference the filing does not itemize

-1.0 pts

Effective rate

-0.0%

One point is 1% of profit before tax. The lines are as the company states them in the notes to its annual report. The filing

Claims ahead of shareholders

What stands between the business and its shareholders besides the debt, and the financial assets on the other side, from the latest balance sheet.

Other than debt, no claim large enough to list ranks ahead of the shares.

From the balance sheet of September 30, 2026. The retirement and environmental lines and the pension deficit come from the latest annual report when the quarter's filing does not state them, each with its own date. Market value at the price of November 16, 2026. A line is listed when it is at least 0.5% of the market value. A description of the balance sheet, not a valuation.

Earnings quality

How the reported earnings were made, read from the filings. A description, not a score: our tests found no link between these measures and later share returns.

Receivables and inventory against sales

In the quarter to Sep 30, 2026, sales were +53.1% on the same quarter a year earlier, and receivables +14.8%. Inventory was -33.7%, against +30.9% for the cost of sales.

a year earlier 49 days
36 days
a year earlier 207 days
105 days

Balances at Sep 30, 2026 and Sep 30, 2025, against the sales and cost of sales of the quarter ending on each date; a fourth quarter is the fiscal year less its first nine months. Same quarter against same quarter, so the season is the same.

The earnings per share split is not shown: it needs a profit before tax in both years, since a tax rate on a loss has no meaning as a source.

The allowance for doubtful accounts is not shown: the company does not tag it in its structured filings.

The tax part is not shown: a figure it needs is missing from the company's structured filings.

A reading is called out when it is above the 90th percentile of the same reading across the S&P 500, or, for a fall, below the 10th, as measured on 9 November 2026. Each part uses only the company's own filings.

The full analysis

What do Avita Medical's filings show?

These are Avita Medical's figures from its filings. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about RCEL's financials

Didn't find what you were looking for?

Ask us
How much revenue did RCEL have in 2025?

Avita Medical had revenue of $72M and net income of -$49M in fiscal 2025, a net margin of -67.8%.

How much debt does RCEL have?

On December 31, 2025 Avita Medical had total assets of $56M, debt of $43M and shareholders' equity of -$17M.

How much free cash flow does RCEL have?

In fiscal 2025 Avita Medical had cash from operations of -$31M and spent $1.0M on capital expenditure, leaving -$32M of free cash flow.

Where are the figures from?

From Avita Medical, Inc.'s annual and quarterly reports to the SEC, read from the structured data (XBRL) it files itself.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.